Particle Health, an intelligent data platform that aggregates and
delivers actionable patient data and insights to healthcare
companies, and LifeMD, Inc. (Nasdaq: LFMD), a leading provider of
virtual primary care services, today announced the results of their
joint study demonstrating that delivering actionable clinical
insights can save healthcare providers valuable time and streamline
the patient weight management journey. The joint research study
found that Particle’s API platform was able to compliantly review
patient health histories collected from electronic health records
(EHR) to contextualize data effectively and efficiently, and
potentially facilitate informed decision-making, streamline patient
triage and determine eligibility for treatment with Glucagon-Like
Peptide-1 (GLP-1) drugs.
In collaboration with LifeMD, Particle leveraged clinical data
to identify those patients with a higher likelihood of meeting the
clinical criteria for a GLP-1 drug. The Particle platform’s data
analysis delivered clinical insights that identified 53% of
individuals as requiring a physician touchpoint to acquire more
data. 31% were deemed ineligible for GLP-1 therapy as 12% had a
body mass index (BMI) below the minimal clinical threshold, 19% had
a BMI between 27-30 but lacked additional weight-related
comorbidities and one patient had a history of pancreatitis. The
remaining 16% were ruled potential candidates for GLP-1 agonist
use. These findings potentially save physicians time that would
have otherwise been used determining medication appropriateness. As
a result of Particle’s actionable insights, the patients who were
excluded from medication therapy could be redirected to other
weight management resources, as appropriate.
“The Particle and LifeMD study proved that actionable data
insights can be derived from comprehensive EHR data, which can play
a critical role in helping healthcare providers quickly navigate
patient journeys and inform care decisions,” said Jason
Prestinario, CEO of Particle Health. “We are thrilled to be part of
this exciting research and look forward to pursuing similar
endeavors that will allow us to demonstrate how healthcare provider
access to complete medical data empowers clinical teams. The
ability to get a 360-degree view of the patient to spot
unidentified care gaps can help providers drive cost reductions,
manage risk and improve patient outcomes.”
“LifeMD’s mission is to elevate access to quality medical care –
which starts with transforming healthcare so that it is more
patient-centric, affordable and convenient,” said Dennis Wijnker,
Chief Technology Officer of LifeMD. “With this study we were able
to leverage the Particle platform to explore the potential for
identifying patients that would most benefit from GLP-1 therapy,
and eliminating those who would not. This exercise could lead to
substantial cost and time savings for providers, and appropriate
care for patients.”
To view the Particle and LifeMD GLP-1 case study results in
full, please visit:
http://www.particlehealth.com/resources/lifemd
About Particle Health
Particle Health has built the integrations and APIs that enable
a modern, seamless data experience for healthcare companies, with a
mission to unlock the power of medical records in an intelligent
platform that focuses health back on the patient.
Learn more about Particle at: https://www.particlehealth.com/ or
access the press kit at
https://go.particlehealth.com/press-kit.
About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD
offers telemedicine, laboratory and pharmacy services, and
specialized treatment across more than 200 conditions, including
primary care, men’s health, women’s health, allergy & asthma,
and dermatology. Leveraging a vertically-integrated, proprietary
digital care platform, a 50-state affiliated medical group, and a
US-based patient care center, LifeMD is elevating healthcare by
increasing access to top-notch and affordable care. For more
information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking
Statements
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended;
Section 21E of the Securities Exchange Act of 1934, as amended; and
the safe harbor provision of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements contained in this
news release may be identified by the use of words such as:
“believe,” “expect,” “anticipate,” “project,” “should,” “plan,”
“will,” “may,” “intend,” “estimate,” predict,” “continue,” and
“potential,” or, in each case, their negative or other variations
or comparable terminology referencing future periods. Examples of
forward-looking statements include, but are not limited to,
statements regarding our financial outlook and guidance, short and
long-term business performance and operations, future revenues and
earnings, regulatory developments, legal events or outcomes,
ability to comply with complex and evolving regulations, market
conditions and trends, new or expanded products and offerings,
growth strategies, underlying assumptions, and the effects of any
of the foregoing on our future results of operations or financial
condition.
Forward-looking statements are not historical facts and are not
assurances of future performance. Rather, these statements are
based on our current expectations, beliefs, and assumptions
regarding future plans and strategies, projections, anticipated and
unanticipated events and trends, the economy, and other future
conditions, including the impact of any of the aforementioned on
our future business. As forward-looking statements relate to the
future, they are subject to inherent risk, uncertainties, and
changes in circumstances and assumptions that are difficult to
predict, including some of which are out of our control.
Consequently, our actual results, performance, and financial
condition may differ materially from those indicated in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, “Risk Factors” identified in our filings
with the Securities and Exchange Commission, including, but not
limited to, our most recently filed Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and any amendments thereto. Even if
our actual results, performance, or financial condition are
consistent with forward-looking statements contained in such
filings, they may not be indicative of our actual results,
performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based
on information currently available to us as of the date on which
this release is made. We undertake no obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as may be required
under applicable law or regulation.
Particle Health Contacts:
Media Contactmarketing@particlehealth.com
LifeMD Contacts:
Company ContactLifeMD, Inc.Marc Benathen,
CFOmarc@lifemd.com
Media Contactpress@lifemd.com
LifeMD (NASDAQ:LFMD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
LifeMD (NASDAQ:LFMD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024